Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Vadimezan™
ASA404 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ASA404 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ASA404 | DRUG | - |
Inclusion criteria: 1. Histologically or cytologically confirmed non-small cell carcinoma of the lung. 2. Newly diagnosed Stage IIIb disease or Stage IV disease 3. No prior treatment for Stage IIIb/IV non-small cell carcinoma of the lung (Note: Prior neoadjuvant or adjuvant chemotherapy within 6 mo...
Top 20 of 90 competitors
ASA404 is an investigational small molecule being studied for the treatment of Non-small Cell Lung Cancer (NSCLC). It is administered intravenously in combination with paclitaxel and carboplatin. As of the available data, ASA404 is in Phase 1 clinical development and has not been approved by regulatory authorities.
ASA404 is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is an investigational oncology small molecule, and its development is currently in the early clinical stage.
ASA404 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The Phase 1 trial for ASA404 has been completed, and the drug remains under investigation for Non-small Cell Lung Cancer.
ASA404 has one completed clinical trial, registered as NCT00674102. This was an open-label, Phase 1 trial that evaluated intravenous ASA404 in combination with paclitaxel and carboplatin in Japanese patients with Non-small Cell Lung Cancer. The trial enrolled 15 participants and was conducted in Japan.
ASA404 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Non-small Cell Lung Cancer. The available data shows one completed Phase 1 trial, but no approval status has been established, and the drug remains under clinical investigation.